Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.

MLA

Šímová, J., et al. “Immunotherapy Augments the Effect of 5-Azacytidine on HPV16-Associated Tumours with Different MHC Class I-Expression Status.” British Journal of Cancer, vol. 105, no. 10, Nov. 2011, pp. 1533–41. EBSCOhost, https://doi.org/10.1038/bjc.2011.428.

APA

Šímová, J., Polláková, V., Indrová, M., Mikyšková, R., Bieblová, J., Štěpánek, I., Bubeník, J., Reiniš, M., Símová, J., Polláková, V., Indrová, M., Mikyšková, R., Bieblová, J., Stěpánek, I., Bubeník, J., & Reiniš, M. (2011). Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. British Journal of Cancer, 105(10), 1533–1541. https://doi.org/10.1038/bjc.2011.428

Chicago

Šímová, J, V Polláková, M Indrová, R Mikyšková, J Bieblová, I Štěpánek, J Bubeník, et al. 2011. “Immunotherapy Augments the Effect of 5-Azacytidine on HPV16-Associated Tumours with Different MHC Class I-Expression Status.” British Journal of Cancer 105 (10): 1533–41. doi:10.1038/bjc.2011.428.